Using observational epidemiology to evaluate COVID-19 vaccines : integrating traditional methods with new data sources and tools
© 2021. The Canadian Public Health Association..
Although clinical trials are necessary for vaccine approval, observational epidemiology will be required to evaluate the long-term effectiveness, safety, and population impacts of newly approved COVID-19 vaccines under real-world field conditions. In this commentary, I argue that a hybrid approach that combines new data sources and tools, including COVID-19 vaccine registries, with traditional epidemiological methods will be needed to evaluate COVID-19 vaccines using observational epidemiology. Wherever possible, primary data collection, active surveillance, and linkage with existing population-based cohorts should be leveraged to supplement secondary data sources and passive surveillance systems. Evidence-informed public health decision making around provincial COVID-19 immunization programs will need to account for potential biases, incomplete or conflicting information, and heterogeneity across subpopulations.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
---|---|
Enthalten in: |
Canadian journal of public health = Revue canadienne de sante publique - 112(2021), 5 vom: 23. Okt., Seite 867-871 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chambers, Catharine [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
Date Completed 22.10.2021 Date Revised 07.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.17269/s41997-021-00554-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM32708068X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM32708068X | ||
003 | DE-627 | ||
005 | 20231225200001.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.17269/s41997-021-00554-z |2 doi | |
028 | 5 | 2 | |a pubmed24n1090.xml |
035 | |a (DE-627)NLM32708068X | ||
035 | |a (NLM)34160784 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Chambers, Catharine |e verfasserin |4 aut | |
245 | 1 | 0 | |a Using observational epidemiology to evaluate COVID-19 vaccines |b integrating traditional methods with new data sources and tools |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.10.2021 | ||
500 | |a Date Revised 07.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Canadian Public Health Association. | ||
520 | |a Although clinical trials are necessary for vaccine approval, observational epidemiology will be required to evaluate the long-term effectiveness, safety, and population impacts of newly approved COVID-19 vaccines under real-world field conditions. In this commentary, I argue that a hybrid approach that combines new data sources and tools, including COVID-19 vaccine registries, with traditional epidemiological methods will be needed to evaluate COVID-19 vaccines using observational epidemiology. Wherever possible, primary data collection, active surveillance, and linkage with existing population-based cohorts should be leveraged to supplement secondary data sources and passive surveillance systems. Evidence-informed public health decision making around provincial COVID-19 immunization programs will need to account for potential biases, incomplete or conflicting information, and heterogeneity across subpopulations | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Epidemiology | |
650 | 4 | |a Observational study | |
650 | 4 | |a Public health | |
650 | 4 | |a Vaccine | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
773 | 0 | 8 | |i Enthalten in |t Canadian journal of public health = Revue canadienne de sante publique |d 1945 |g 112(2021), 5 vom: 23. Okt., Seite 867-871 |w (DE-627)NLM00009854X |x 1920-7476 |7 nnns |
773 | 1 | 8 | |g volume:112 |g year:2021 |g number:5 |g day:23 |g month:10 |g pages:867-871 |
856 | 4 | 0 | |u http://dx.doi.org/10.17269/s41997-021-00554-z |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 112 |j 2021 |e 5 |b 23 |c 10 |h 867-871 |